APHB - AmpliPhi Biosciences Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
1.07
-0.03 (-2.73%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.10
Open1.13
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.06 - 1.11
52 Week Range0.30 - 5.80
Volume335,548
Avg. Volume499,567
Market Cap10.164M
Beta2.57
PE Ratio (TTM)N/A
EPS (TTM)-4.84
Earnings DateMar 26, 2018 - Mar 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Business Wire10 days ago

    AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a public offering of 4,000,000 shares of its common stock, offered at a price to the public of $1.00 per share, for gross proceeds of $4.0 million, before deducting placement agent fees and offering expenses ...

  • Business Wire10 days ago

    AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends to offer shares of its common stock in a public offering.

  • Zacks Small Cap Research15 days ago

    APHB: Reports Positive Interim Results for Expanded Access Program

    A total of seven patients with serious or life-threatening infections, which were not responding to antibiotic therapy, were treated with AB-SA01 (n=4) or AB-PA01 (n=3). AmpliPhi is developing bacteriophage therapeutics for the treatment of bacterial infections. Bacteriophages are viruses that infect, replicate in, and kill bacterial cells while not harming eukaryotic cells.

  • Business Wire16 days ago

    AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced topline results for the first seven patients treated under its ongoing single-patient expanded access program.

  • Business Wire17 days ago

    AmpliPhi Biosciences to Present at Biotech Showcase 2018

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that Paul C.

  • Best NasdaqGM Growth Stocks
    Simply Wall St.last month

    Best NasdaqGM Growth Stocks

    Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Alder Biopharmaceuticals and OceanFirst Financial are deemed to be superiorRead More...

  • Business Wirelast month

    AmpliPhi Biosciences Provides Corporate and Strategic Update

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced its progress in 2017 and near-term strategic goals and initiatives.

  • AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube2 months ago

    AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis AmpliPhi Biosciences Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of AmpliPhi Biosciences Corp. – Cerus Corporation and Asterias Biotherapeutics Inc Class A (CERS-US and AST-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • Business Wire2 months ago

    AmpliPhi Biosciences to Present at LD Micro 10th Annual Main Event

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that Paul C.

  • Top Growth Stocks in November
    Simply Wall St.2 months ago

    Top Growth Stocks in November

    High growth companies such as AmpliPhi Biosciences and Alder Biopharmaceuticals has a positive future outlook in terms of their returns, profitability and cash flows. The prospects of these companies tendRead More...

  • Zacks Small Cap Research2 months ago

    APHB: Six Patients Treated So Far With AB-SA01 and AB-PA01 Under Expanded Access Programs

    AmpliPhi Biosciences Corp. (APHB) is developing bacteriophage therapeutics for the treatment of bacterial infections. In addition to offering hope to patients that have exhausted all treatment options, clinical data derived from single patient expanded access cases will help to support the utility of phage therapy when the company engages the U.S. Food and Drug Administration (FDA) in discussions for a regulatory path forward for approval of phage therapies.

  • Business Wire2 months ago

    AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the third quarter ended September 30, 2017.

  • Business Wire2 months ago

    AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday, November 14, 2017 beginning at 4:30 p.m.

  • Business Wire3 months ago

    AmpliPhi Biosciences to Participate in the BIO-Europe 2017 Conference

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that Igor P.

  • Business Wire3 months ago

    AmpliPhi Biosciences to Participate in Two Upcoming Conferences

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bac

  • Business Wire4 months ago

    AmpliPhi Biosciences Announces Publication of Preclinical Data for AB-PA01 Showing Activity in Reducing Biofilms of Pseudomonas Aeruginosa

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced the publication of preclinical data demonstrating the activity of AB-PA01 in reducing biofilms.

  • Business Wire4 months ago

    AmpliPhi Biosciences’ CEO to Moderate Panel Discussion at Upcoming Anti-Infectives Rx Conference

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that CEO Paul C.

  • Business Wire4 months ago

    AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces the first-in-human intravenous administration of AmpliPhi’s drug candidate AB-SA01.

  • Business Wire4 months ago

    AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that it has received a Research and Development Tax Incentive cash rebate of USD $2.0 million from the Australian Tax Office based on the Company’s R&D spending in Australia during 2016.

  • Business Wire5 months ago

    AmpliPhi Biosciences to Present at Rodman & Renshaw 19th Annual Global Investment Conference

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that Paul C.

  • Zacks Small Cap Research5 months ago

    APHB: Patient Treated Under Expanded Access Protocol With AB-PA01

    AmpliPhi Biosciences Corp. (APHB) is developing bacteriophage therapeutics for the treatment of bacterial infections. AmpliPhi’s strategy is to use single patient expanded access protocols to derive real-world data using phage therapies in patients suffering from severe, multidrug-resistant infections. In addition to offering hope to patients that have exhausted all treatment options, clinical data derived from single patient expanded access cases will help to support the utility of phage therapy when the company engages the U.S. Food and Drug Administration (FDA) in discussions for a regulatory path forward for approval of phage therapies.

  • Business Wire5 months ago

    AmpliPhi Biosciences Announces Publication of Bacteriophage Case Study for Life-Threatening Antibiotic-Resistant Infection

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces publication of a case study highlighting the successful treatment of a critically ill patient with a multidrug-resistant Acinetobacter baumannii (A.

  • AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube5 months ago

    AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AmpliPhi Biosciences Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AmpliPhi Biosciences Corp. – Cerus Corporation, CEL-SCI Corporation, Asterias Biotherapeutics Inc Class A and Array BioPharma Inc. (CERS-US, CVM-US, AST-US and ARRY-US) that have also reported for this ... Read more (Read more...)

  • Business Wire5 months ago

    AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights

    AmpliPhi Biosciences Corporation , a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the three and six months ended June 30, 2017 and business highlights.

  • ACCESSWIRE5 months ago

    Investor Network: AmpliPhi BioSciences Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2017 / AmpliPhi BioSciences Corporation (NYSE American: APHB) will be discussing their earnings results in their Q2 Earnings Call to be held on Monday, August 14, ...